Di Zhu

Di Zhu

Auto-generated profile, based on publicly available information

Di Zhu

Research Unit of Evidence-Based Evaluation and Guidelines, Chinese Academy of Medical Sciences, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
XLXufei Luo
Xufei Luo
FCFengxian Chen
Fengxian Chen
DZDi Zhu
Di Zhu
LWLing Wang
Ling Wang
ZWZijun Wang
Zijun Wang
YCYaolong Chen
Yaolong Chen
Large language models (LLMs) such as ChatGPT have become widely applied in the field of medical research. In the process of conducting systematic reviews, similar tools can be used to expedite various steps, including defining clinical questions, performing the literature search, document screening, information extraction, and language refinement, thereby conserving resources and enhancing efficiency. However, when using LLMs, attention should be paid to transparent reporting, distinguishing between genuine and false content, and avoiding academic misconduct. In this viewpoint, we highlight the potential roles of LLMs in the creation of systematic reviews and meta-analyses, elucidating their advantages, limitations, and future research directions, aiming to provide insights and guidance for authors planning systematic reviews and meta-analyses.

1 August 2023 in Psychiatry Research
Verified
Journal Article
Open access
XLXufei Luo
Xufei Luo
DZDi Zhu
Di Zhu
JLJitao Li
Jitao Li
MRMengjuan Ren
Mengjuan Ren
YLYunlan Liu
Yunlan Liu
YCYaolong Chen
Yaolong Chen
Sertraline has been shown to be effective in the treatment of depression. However, the relationship between the dosage of sertraline and its efficacy and safety are unclear. We identified RCTs that compared sertraline with placebo for the treatment of depression, conducted conventional meta-analyses on the efficacy and safety of sertraline, and assessed the nonlinear dose-response relationship between sertraline dosage and the changes in HAM-D and CGI-S scores, dropout from care for any reason or due to adverse effects, and the rate of adverse effects, using a 1-stage restricted cubic spline regression model. Twenty-one RCTs involving 4,235 patients were included. The pooled mean differences (MD) in the change in HAM-D total score [MD=-2.34, 95% confidence interval (CI) -2.93, -1.76], CGI-S score and MADRS score, but also the dropout rate for adverse effects, and rate of adverse effects were higher in sertraline group. The therapeutic response of sertraline for treating depression increased with the dosage. Meanwhile, the risk of total adverse reactions slightly decreased between 50 and 150 mg, and increased at doses above 150 mg. The dose-dependence of both efficacy and safety need to be considered when choosing the optimal dosage of sertraline.

1 July 2019
Verified
Conference Paper
Closed access
DZDi Zhu
Di Zhu
LZLei Zhang
Lei Zhang
XDXiaolong Dong
Xiaolong Dong
RYRisheng Yun
Risheng Yun
WLWenming Lin
Wenming Lin
SLShuyan Lang
Shuyan Lang
After the launching of CFOSAT (China-France Oceanography Satellite), calibrations of the SCAT (scatterometer onboard the CFOSAT) are carried out to modify the bias of the observed NRCS (normalized radar cross section). In this paper, some preliminary calibration results of CFOSAT SCAT are presented, including both internal calibration onboard the CFOSAT and external calibration on the ground. First, the onboard calibration signals and noise signals are analyzed to ensure the SCAT works in a steady status. Then, calibrations on NRCS are carried out by using the SCAT data from Amazon rainforest area. Furthermore, Calibrations using transponders will be carried out at Inner-Mongolian. Preliminary calibration results show that the NRCS of CFOSAT SCAT are compliable with the NRCS of NSCAT.

14 August 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
ZWZijun Wang
Zijun Wang
LWLing Wang
Ling Wang
BWBingyi Wang
Bingyi Wang
HHHongfeng He
Hongfeng He
ZLZhewei Li
Zhewei Li
JEJanne Estill
Janne Estill
Background: The burden of multimorbidity is increasing globally, which complicates the use of guidelines in clinical practice and health care: practitioners may need to increasingly refer to multiple guidelines with potentially conflicting recommendations. Objective: We aim to develop a guideline-based decision support framework for the management of patients with multimorbidity to help clinicians efficiently evaluate, select, and adapt recommendations focusing on the different comorbidities and aspects of multimorbidity. Methods: We will conduct the project using the following steps: (1) needs assessment (searching published literature and documents on guideline use in multimorbidity care through the study initiators, and assessing the necessity of developing a comprehensive decision-making framework focusing on multimorbidity in a broad sense), (2) establishing international working groups (a coordination team, an evidence support group, and a consensus group) by leveraging existing participants’ networks and inviting experts with relevant academic publications or activities, (3) conducting literature reviews of multimorbidity guidelines and original qualitative research involving interest-holders in multimorbidity care and/or guideline development to formulate an initial draft framework, (4) a consensus process including an expert survey and a consensus meeting, (5) formulating and releasing the final framework, and (6) testing the framework (collecting feedback through educating health professionals in different settings and applying the framework in practice to evaluate and improve it). We plan to complete the project within 3 years. Results: The project has started in March 2024 and is due to conclude in June 2026. As of May 2025, we have finished the literature reviews and qualitative studies and are currently conducting the first round of the expert survey. Conclusions: This framework will help clinicians from all levels of health care institutions to make decisions in the management of patients with multimorbidity based on the latest available evidence, and to reduce potential health risks to their patients. One limitation of this framework is that such a broad framework may not fully fit all disease combinations or realistic situations. To reduce the degree of inapplicability, after completion of the framework, we will continue to monitor its use with regular updates as needed. International Registered Report Identifier (IRRID): DERR1-10.2196/63339

20 February 2024 in JMIR Preprints
Verified
Preprint
Open access
XLXufei Luo
Xufei Luo
FCFengxian Chen
Fengxian Chen
DZDi Zhu
Di Zhu
LWLing Wang
Ling Wang
ZWZijun Wang
Zijun Wang
YCYaolong Chen
Yaolong Chen
UNSTRUCTURED Large language models (LLMs) such as ChatGPT have become widely applied in the field of medical research. In the process of conducting systematic reviews, similar tools can be used to expedite various steps, including defining clinical questions, performing the literature search, document screening, information extraction, and language refinement, thereby conserving resources and enhancing efficiency. However, when using LLMs, attention should be paid to transparent reporting, distinguishing between genuine and false content, and avoiding academic misconduct. In this viewpoint, we highlight the potential roles of LLMs in the creation of systematic reviews and meta-analyses, elucidating their advantages, limitations, and future research directions, aiming to provide insights and guidance for authors planning systematic reviews and meta-analyses.

17 June 2024 in JMIR Preprints
Verified
Preprint
Open access
ZWZijun Wang
Zijun Wang
LWLing Wang
Ling Wang
BWBingyi Wang
Bingyi Wang
HHHongfeng He
Hongfeng He
ZLZhewei Li
Zhewei Li
JEJanne Estill
Janne Estill
BACKGROUND The burden of multimorbidity is increasing globally, which complicates the use of guidelines in clinical practice and health care: practitioners may need to increasingly refer to multiple guidelines with potentially conflicting recommendations. OBJECTIVE We aim to develop a guideline-based decision support framework for the management of patients with multimorbidity to help clinicians efficiently evaluate, select, and adapt recommendations focusing on the different comorbidities and aspects of multimorbidity. METHODS We will conduct the project using the following steps: (1) needs assessment (searching published literature and documents on guideline use in multimorbidity care through the study initiators, and assessing the necessity of developing a comprehensive decision-making framework focusing on multimorbidity in a broad sense), (2) establishing international working groups (a coordination team, an evidence support group, and a consensus group) by leveraging existing participants’ networks and inviting experts with relevant academic publications or activities, (3) conducting literature reviews of multimorbidity guidelines and original qualitative research involving interest-holders in multimorbidity care and/or guideline development to formulate an initial draft framework, (4) a consensus process including an expert survey and a consensus meeting, (5) formulating and releasing the final framework, and (6) testing the framework (collecting feedback through educating health professionals in different settings and applying the framework in practice to evaluate and improve it). We plan to complete the project within 3 years. RESULTS The project has started in March 2024 and is due to conclude in June 2026. As of May 2025, we have finished the literature reviews and qualitative studies and are currently conducting the first round of the expert survey. CONCLUSIONS This framework will help clinicians from all levels of health care institutions to make decisions in the management of patients with multimorbidity based on the latest available evidence, and to reduce potential health risks to their patients. One limitation of this framework is that such a broad framework may not fully fit all disease combinations or realistic situations. To reduce the degree of inapplicability, after completion of the framework, we will continue to monitor its use with regular updates as needed. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/63339